Cetrorelix Acetate
FDA-approved product (powder, subcutaneous), marketed as Cetrorelix Acetate, Cetrotide.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Ovulation Inhibition
- Positive regulation of ovulation
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Anti-gonadotropin-releasing hormones
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis62.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cetrorelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.
NCT01948804 · start 2014-01
Registered record
- Registry ID
- NCT01948804
- Conditions
- Poor Responders Undergoing IVF
- Interventions
- GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG); microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono); Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma); GnRH antagonist protocol (Cetrotide, Serono)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2014-01
- Completion
- Not recorded
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPoor Responders Undergoing IVFInterventionGnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG); microdose flare-up protocol (Lucrin +4 morePhasePhase 4Registry statusUnknownEndometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles
NCT01798862 · start 2013-03
Registered record
- Registry ID
- NCT01798862
- Conditions
- Repeated Implantation Failures
- Interventions
- Endometrial injury by hysteroscopy or pipelle sampling; Proceed to COH directly
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2013-03
- Completion
- 2016-06
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRepeated Implantation FailuresInterventionEndometrial injury by hysteroscopy or pipelle sampling; Proceed to COH directlyPhasePhase 2 / Phase 3Registry statusCompletedUse of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)
NCT01709942 · start 2012-11
Registered record
- Registry ID
- NCT01709942
- Conditions
- PCOS; OHSS; INFERTILITY
- Interventions
- degarelix (long acting GnRH antagonist); cetrorelix 0.25mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-11
- Completion
- 2015-12
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPCOS; OHSS; INFERTILITYInterventiondegarelix (long acting GnRH antagonist); cetrorelix 0.25mgPhasePhase 3Registry statusCompletedComparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression
NCT01565265 · start 2012-04
Registered record
- Registry ID
- NCT01565265
- Conditions
- Female Infertility Due to Nonimplantation of Ovum; Complications Associated With Artificial Fertilization
- Interventions
- Pergoveris in long protocol with GnRH agonist; Pergoveris in GnRH antagonist protocol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2012-04
- Completion
- 2013-12
- Enrolment
- 5
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFemale Infertility Due to Nonimplantation of Ovum; Complications Associated With Artificial FertilizationInterventionPergoveris in long protocol with GnRH agonist; Pergoveris in GnRH antagonist protocolPhaseNot applicableRegistry statusCompletedStudy on Influence of Leutinizing Hormone (LH) on Oocyte Maturity
NCT01595334 · start 2012-04
Registered record
- Registry ID
- NCT01595334
- Conditions
- Infertility
- Interventions
- Cetrorelix; Luprolide Acetate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2012-04
- Completion
- 2012-11
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertilityInterventionCetrorelix; Luprolide AcetatePhaseNot applicableRegistry statusUnknownAddition of Prednisolone and Heparin in Patients Undergoing IVF With Failed IVF Cycles
NCT01590173 · start 2012-01
Registered record
- Registry ID
- NCT01590173
- Conditions
- Infertility
- Interventions
- Prednisolone and Heparin during COH for IVF; COH for IVF
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2016-07
- Enrolment
- 86
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertilityInterventionPrednisolone and Heparin during COH for IVF; COH for IVFPhasePhase 2 / Phase 3Registry statusCompletedSynchronization of Ovarian Stimulation for in Vitro Fertilization With Follicular Wave Emergence
NCT01668056 · start 2012-01
Registered record
- Registry ID
- NCT01668056
- Conditions
- Infertility
- Interventions
- Ovulation induction with choriogonadotropin alfa; Aspiration of the dominant follicle; Control
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2012-01
- Completion
- 2014-12
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertilityInterventionOvulation induction with choriogonadotropin alfa; Aspiration of the dominant follicle; ControlPhaseNot applicableRegistry statusUnknownGonadotropin Type in Ovarian Stimulation
NCT02437032 · start 2009-04
Registered record
- Registry ID
- NCT02437032
- Conditions
- Infertility
- Interventions
- recombinant FSH; Urinary FSH; hMG
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-04
- Completion
- 2012-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertilityInterventionrecombinant FSH; Urinary FSH; hMGPhasePhase 4Registry statusCompletedThe Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
NCT00867659 · start 2009-03
Registered record
- Registry ID
- NCT00867659
- Conditions
- Ovarian Hyperstimulation Syndrome
- Interventions
- Cetrotide acetate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2009-03
- Completion
- 2011-10
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOvarian Hyperstimulation SyndromeInterventionCetrotide acetatePhaseNot applicableRegistry statusCompletedExtended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Poor Responders Undergoing IVF-ET
NCT01219153 · start 2008-09
Registered record
- Registry ID
- NCT01219153
- Conditions
- Infertility
- Interventions
- Extended high dose letrozole regimen /GnRH antagonist protocol; Short low dose letrozole regimen /GnRH antagonist protocol
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-09
- Completion
- 2010-12
- Enrolment
- 136
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertilityInterventionExtended high dose letrozole regimen /GnRH antagonist protocol; Short low dose letrozole regimen /GnRH antagonist protocolPhasePhase 2Registry statusCompletedCetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
NCT00670306 · start 2008-03
Registered record
- Registry ID
- NCT00670306
- Conditions
- Benign Prostatic Hypertrophy
- Interventions
- Cetrorelix Pamoate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-03
- Completion
- 2009-08
- Enrolment
- 528
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HypertrophyInterventionCetrorelix PamoatePhasePhase 3Registry statusCompletedGonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study
NCT00571870 · start 2007-11
Registered record
- Registry ID
- NCT00571870
- Conditions
- Infertility
- Interventions
- cetrorelix acetate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2007-11
- Completion
- 2009-08
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertilityInterventioncetrorelix acetatePhaseNot applicableRegistry statusCompletedA Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age
NCT01079949 · start 2007-11
Registered record
- Registry ID
- NCT01079949
- Conditions
- Infertility; Ovulation Induction
- Interventions
- r-hLH + r-hFSH; r-hFSH; Recombinant Human Choriogonadotropin (r-hCG); GnRH antagonist
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2007-11
- Completion
- 2010-10
- Enrolment
- 93
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertility; Ovulation InductionInterventionr-hLH + r-hFSH; r-hFSH; Recombinant Human Choriogonadotropin (r-hCG); GnRH antagonistPhasePhase 2Registry statusTerminatedSynchronization of Follicle Wave Emergence and Ovarian Stimulation
NCT00439829 · start 2007-02
Registered record
- Registry ID
- NCT00439829
- Conditions
- Infertility
- Interventions
- Gonal F; Luveris; Cetrotide; hCG
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-02
- Completion
- 2010-05
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertilityInterventionGonal F; Luveris; Cetrotide; hCGPhasePhase 4Registry statusCompletedGnRH Antagonist to Prepare Recipients for Embryo Transfer
NCT00460642 · start 2007-01
Registered record
- Registry ID
- NCT00460642
- Conditions
- Infertility
- Interventions
- GnRH Antagonist (Cetrotide)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2009-12
- Enrolment
- 130
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertilityInterventionGnRH Antagonist (Cetrotide)PhaseNot applicableRegistry statusCompleted